¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Journal of clinical monitoring and computing."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • clinical target volume
    ÀÓ»óÇ¥ÀûüÀû
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • good clinical practice
    ÀǾàǰÀÓ»ó½ÃÇè°ü¸®±âÁØ
  • structured clinical interview
    ±¸Á¶È­ÀÓ»ó¸éÁ¢
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • randomized clinical trial
    ¹«ÀÛÀ§ÀÓ»ó½ÇÇè
  • structured clinical interview
    ±¸Á¶È­µÈ ÀÓ»ó¸éÁ¢(ìúßÉØüïÈ).
  • validity of clinical study
  • acute and late normal tissue effects
    Á¤»óÁ¶Á÷ ±Þ¼º¿µÇâ, Á¤»óÁ¶Á÷ ¸¸¼º ¿µÇâ
  • alternate hot and cold caloric examination
    ³Ã¿Â±³´ë(¿Âµµ)Àڱذ˻ç(ÕÒè®Îßû»è®öôô§Ð½ËþÞÛ).
  • ambient temperature and pressure saturated with water vapor =ATP
    ½Ç¿Â´ë±â¾Ð ¼öÁõ±â Æ÷È­»óÅÂ
  • american society of therapeutic radiology and onco
    logy (ASTRO) ¹Ì±¹¹æ»ç¼±Á¾¾çÇÐȸ
  • aphasic and apraxic syndrome
    ½Ç¾î½ÇÇàÁõÈıº(ã÷åÞãùú¼ñøý¦ÏØ).
  • aphthous fever =foot and mouth disease
    ¾ÆÇÁŸ¼º¿­(¡­æð).
  • atherosclerosis,hyperlipidemia and diet
    °íÁöÇ÷Áõ(ÍÔò·úìñø)°ú ½ÄÀÌ(ãÝìÈ)
  • atmospheric temperature and pressure
    (´ë±â)Ç¥ÁØ»óÅÂ.
  • atrophoderma of Pasini and Pierini
    ÆÄ½Ã´Ï ÇÇ¿¡¸®´Ï ÇǺΠÀ§ÃàÁõ
  • auscultation and percussion =A & P
    ûÁø(ôéòà) ¹× ŸÁø(¡­öèòà).
  • babbling and lalling stage
    ÀçÀ߰Ÿ², ³²¾î±â(Õ½åÞÑ¢).
  • bites and stings
    ±³»ó°ú ÀÚ»ó.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
SMBG Self Monitoring of Blood Glucose
ARMS adverse reaction monitoring system; amplification refractory mutation system
BEAM brain electrical activity monitoring
BGM bedside glucose monitoring
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
GC--MS--SIM gas chromatography--mass spectrometry--selected ion monitoring
GC-SIM gas chromatography selected ion monitoring
ACTG AIDS Clinical Trials Group
ASCO American Society of Clinical Oncology
CAI Clinical Activity Index
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • pseudoepitheliomatous keratotic and micaceous balanitis
    °¡¼º »óÇÇÁ¾¼º ¼®¸é °¢È­ ±ÍµÎ¿°
  • quick cooling and grinding
    ±Þ³Ã°ú ¿¬¸¶
  • resorption and exfoliation
    Èí¼ö ¹× Å»¶ô±â
  • resuscitation bag and mask
    ¼Ò»ý¿ë ¹é°ú ¸¶½ºÅ©
  • right and left laterotrusive movement
    Á¿ì Ãø¹æ ¿îµ¿
  • right and left margin of uterus
    ¿À¸¥, ¿Þ Àڱà °¡ÀåÀÚ¸®
  • safety regulation and standard
    ¾ÈÀü Á¶Àý ¹× Ç¥ÁØ
  • salt and pepper appearance
    ¼Ò±Ý ÈÄÃß°¡·ç ¸ð¾ç
  • scalel handles and blade
    ¿Ü°ú¿ë Ä®
    ¿Ü°úÀû Àý°³¸¦ À§ÇØ »ç¿ëµÇ´Â Ä®·Î ÁÖ·Î 3¹ø Ä®´ë¿Í 15¹ø Ä®³¯À» »ç¿ëÇÑ´Ù.
  • separation of child and parents
    Áø·á ÁßÀÇ ¸ðÀÚ ºÐ¸®
  • signs and symptoms
    ¡ÈÄ¿Í Áõ»ó
  • spatial and temporal
    ½Ã°ø
  • subepithelial deposit and sclerosis
    »óÇÇÇÏ ÃàÀû°ú °æÈ­
  • superior and inferior lobe
    »ó ¹× ÇÏ¿±
  • supportive and symptomatic therapy
    Áõ»ó ¿ä¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
clinical trials, phase II Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase III Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
controlled clinical trial A clinical trial involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicine, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trial is characterised as a randomised controlled trial. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes are simply designated as controlled clinical trials.
(12 Dec 1998)
controlled clinical trials Clinical trials involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicines, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trials are characterised as randomised controlled trials. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are simply designated as controlled clinical trials.
(12 Dec 1998)
cytogenetics, clinical The application of cytogenetics to clinical medicine. For example, clinical cytogenetic studies might be done to determine whether a child with possible Down syndrome has an extra chromosome 21.
(12 Dec 1998)
prospective, randomised, double-blind clinical trial <statistics> A clinical trial in which the method for analysing data has been specified in the protocol before the study has begun (prospective), the patients have been randomly assigned to receive either the study drug or alternative treatment, and in which neither the patient nor the physician conducting the study know which treatment is being given to the patient.
(13 Nov 1997)
psychology, clinical The branch of psychology concerned with psychological methods of recognizing and treating behaviour disorders.
(12 Dec 1998)
human clinical trial <pharmacology> Controlled clinical studies in human volunteers to test the safety and efficacy of pharmaceutical candidates.
There are usually three distinct phases of human clinical testing: Phases I, II, and III.
Phase I trials are safety studies of volunteers, usually healthy controls. Phase II trials are studies to confirm safety and study optimum dose and initial efficacy. Phase III trials are studies to prove safety and efficacy in a specific patient population.
(14 Nov 1997)
decision support systems, clinical Computer-based information systems used to integrate clinical and patient information and provide support for decision-making in patient care.
(12 Dec 1998)
disease, clinical A disease with clinical signs and symptoms that can be recognised. As distinct from a subclinical illness without recognizable clinical manifestations. Diabetes, for example, can be subclinical in a person before emerging as a clinical disease.
(12 Dec 1998)
in clinical parlance The term often refers to the posterior funiculus of the spinal cord.
(05 Mar 2000)
epidemiology, clinical Epidemiology focused specifically upon patients.
(12 Dec 1998)
abstracting and indexing Shortening or summarizing of documents; assigning of descriptors for referencing documents.
(12 Dec 1998)
academies and institutes Organizations representing specialised fields which are accepted as authoritative; may be non-governmental, university or an independent research organization, e.g., national academy of sciences, brookings institution, etc.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • cock-and-bull story
    Å͹«´Ï¾ø´Â(Ȳ´ç¹«°èÇÑ) À̾߱â
  • cock-and-hen
    ³²³à È¥ÇÕÀÇ (Ŭ·´µî)
  • coffee-and
    Ä¿ÇÇ¿Í µµ³Ó(°¡Àå ½Ñ ½Ä»ç)
  • come-and-go
    ¿Ô´Ù°¬´ÙÇÔ;¿Õ·¡;º¯Ãµ
  • country-and-western
    ÄÁÆ®¸® ¿þ½ºÅÏ;ÄÁÆ®¸®¹ÂÁ÷(¹Ì±¹ ³²ºÎ¿¡¼­ ¹ß»ýÇÑ ¹Î¼Ó À½¾Ç)
  • cut-and-come-again
    (°í±â µîÀ»)¸î ¹øÀÌ°í º£¾î ¸Ô±â;dzºÎÇÔ;¹«ÁøÀå;¾ç¹èÃßÀÇ ÀÏÁ¾
  • cut-and-dried
    -dry()(¸».°èȹµî)¹Ì¸® ÁغñµÈ;¹Ì¸®°áÁ¤µÈ;½Å¼±ÇÔÀÌ ¾ø´Â;¹«¹Ì°ÇÁ¶ÇÑ;Ȱ±â ¾ø´Â(dull);Ʋ¿¡ ¹ÚÈù;ÁøºÎÇÑ
  • cut-and-thrust
    (°ËÀÌ)º£±â¿Í Â±â °â¿ëÀÇ
  • deaf and dumb
    ³ó¾ÆÀÇ;³ó¾ÆÀÚ(¿ë)ÀÇ
  • dribs and drabs
    ÀûÀº ¾ç
  • gin and tonic
    ÁøÅä´Ð
  • hammer and sickle
    (ÇØ¸Ó¿Í ³´À¸·Î µÈ)¼Ò·Ã ±¹±â
  • haves and havenots
    ÇÙ º¸À¯±¹°ú ºñº¸À¯±¹;(ÀϹÝÀûÀ¸·Î)°¡Áø ÀÚ(³ª¶ó)¿Í °®Áö ¸øÇÑ ÀÚ(³ª¶ó)
  • hen and chickens
    ±äº´²É(²ÜÇ®°ú);µ¢±¼°í¾Æ´ë¼ö¿°(±¤´ë³ª¹°°ú)
  • hole and corner
    ºñ¹ÐÀÇ;Â÷ÂúÀº
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á